公开(公告)号：US20240293469A1

公开(公告)日：2024-09-05

申请号：US18659876

申请日：2024-05-09

申请人： Figene, LLC

发明人： Pete O'Heeron ,  Thomas Ichim

IPC分类号： A61K35/33 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K14/715 ,  C12N5/077 ,  C12N7/00

CPC分类号： A61K35/33 ,  A61K39/0011 ,  A61K45/06 ,  A61P35/00 ,  C07K14/7158 ,  C12N5/0656 ,  C12N7/00 ,  A61K2039/585 ,  C12N2500/02 ,  C12N2710/24134 ,  C12N2710/24171

摘要： Embodiments of the disclosure encompass methods and compositions for treatment of cancer utilizing fibroblasts that have been modified to enhance their ability to deliver one or more anti-cancer agents to an individual in need thereof. In particular embodiments, the fibroblasts have been modified to express one or more chemokine receptors and/or have been exposed to hypoxia to enhance their ability to home to cancer cells. In specific cases the modified fibroblasts are engineered to encompass an oncolytic virus as a tumor inhibitory agent.

公开(公告)号：US20230174586A1

公开(公告)日：2023-06-08

申请号：US17293378

申请日：2019-11-14

申请人： TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE ,  SHIGA UNIVERSITY OF MEDICAL SCIENCE

发明人： Fumihiko YASUI ,  Michinori KOHARA ,  Kenzaburo YAMAJI ,  Yasushi ITOH ,  Kazumasa OGASAWARA ,  Koji ISHII

IPC分类号： C07K14/005 ,  C12N15/86 ,  A61P31/16 ,  A61K39/145

CPC分类号： C07K14/005 ,  A61K39/145 ,  A61P31/16 ,  C12N15/86 ,  A61K2039/5256 ,  C12N2710/24122 ,  C12N2710/24143 ,  C12N2710/24171 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16143 ,  C12N2760/16171

摘要： Provided are: a recombinant vaccinia virus which is effective for the prevention of the development of a disease by the infection by H7 avian influenza virus and has high safety; and a vaccine against H7 avian influenza virus, which comprises the recombinant vaccinia virus. The recombinant vaccinia virus according to the present invention is a recombinant vaccinia virus having such a structure that an expression promoter and the full length or a part of cDNA encoding hemagglutinin protein of H7 avian influenza virus are contained in the genome for vaccinia virus strain DIs.

公开(公告)号：US20180078591A1

公开(公告)日：2018-03-22

申请号：US15565609

申请日：2016-04-18

申请人： Memorial Sloan Kettering Cancer Center

发明人： Liang DENG ,  Jedd WOLCHOK ,  Taha MERGHOUB ,  Stewart SHUMAN ,  Peihong DAI ,  Weiyi WANG

IPC分类号： A61K35/768 ,  C07K16/28 ,  A61K39/395

CPC分类号： A61K35/768 ,  A61K39/12 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/525 ,  A61K2039/5254 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/57 ,  C07K16/2818 ,  C07K16/2827 ,  C12N2710/24122 ,  C12N2710/24132 ,  C12N2710/24134 ,  C12N2710/24171 ,  A61K2300/00

摘要： The present disclosure relates to modified vaccinia Ankara (MVA) virus or MVAAE3L delivered intratumorally or systemically as an anticancer immunotherapeutic agent, alone, or in combination with one or more immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to mobilizing the host's immune system to mount an immune response against the tumor.

公开(公告)号：US20180028635A1

公开(公告)日：2018-02-01

申请号：US15787368

申请日：2017-10-18

申请人： OXFORD UNIVERSITY INNOVATION LIMITED

发明人： Katharine Alice Collins ,  Sarah Catharine Gilbert ,  Adrian Vivian Sinton Hill

IPC分类号： A61K39/015 ,  A61K39/12 ,  C07K16/08 ,  A61K38/16 ,  C12N7/00 ,  C07K16/20 ,  C07K14/445 ,  A61K39/00

CPC分类号： A61K39/015 ,  A61K38/162 ,  A61K39/12 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/5256 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55577 ,  A61K2039/70 ,  C07K14/445 ,  C07K16/082 ,  C07K16/205 ,  C07K2319/00 ,  C07K2319/40 ,  C12N7/00 ,  C12N2710/10041 ,  C12N2710/24121 ,  C12N2710/24134 ,  C12N2710/24141 ,  C12N2710/24143 ,  C12N2710/24171 ,  C12N2730/10134 ,  C12N2730/10171 ,  Y02A50/412

摘要： The present invention provides a particle comprising a fusion protein, wherein the fusion protein comprises at least one NANP repeat (SEQ ID NO: 7), some or all of the C-terminus of the CS protein from Plasmodium falciparum and a hepatitis B surface antigen, and wherein the particle comprises no, or substantially no, free hepatitis B surface antigen protein, and uses thereof.

公开(公告)号：US20170298387A1

公开(公告)日：2017-10-19

申请号：US15514119

申请日：2015-09-25

申请人： The USA, as represented by the Secretary, Department of Health and Human Services

发明人： Bernard MOSS ,  Linda S. WYATT

IPC分类号： C12N15/86 ,  A61K35/76 ,  C12N9/12 ,  A61K39/145 ,  A61K48/00 ,  A61K39/00

CPC分类号： C12N15/86 ,  A61K35/76 ,  A61K39/145 ,  A61K48/0066 ,  A61K2039/5256 ,  C12N9/1247 ,  C12N2710/24122 ,  C12N2710/24143 ,  C12N2710/24151 ,  C12N2710/24171 ,  C12N2760/16134 ,  C12N2760/16171 ,  C12N2799/023 ,  C12N2830/00 ,  C12N2830/001 ,  C12N2830/002 ,  C12N2830/005 ,  C12N2830/55 ,  C12N2830/60 ,  C12Y207/07006

摘要： Expression vectors ideal for use in vaccinating individuals against disease based on vaccinia virus and other chordopoxviruses having high expression of recombinant genes and low expression of vector genes in target animals, and low expression of recombinant genes and high expression of vector genes in cells used for propagation.

公开(公告)号：US20170239345A1

公开(公告)日：2017-08-24

申请号：US15586884

申请日：2017-05-04

申请人： Pharma Green LLC

发明人： Maxim Golovkin

IPC分类号： A61K39/285 ,  C07K14/005 ,  C12N15/82 ,  C12N7/00

CPC分类号： A61K39/285 ,  A61K39/12 ,  A61K39/275 ,  A61K2039/54 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55544 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/575 ,  C07K14/005 ,  C12N7/00 ,  C12N15/8258 ,  C12N2710/24134 ,  C12N2710/24171

摘要： Compositions and methods for producing plant-derived immunogenic compositions that confer immunity against smallpox in a subject are provided. Plants engineered to produce antigenic proteins as well as expression cassettes comprising nucleic acids encoding proteins thereof are described. Methods of immunizing subjects with plant-derived compositions are also provided.

公开(公告)号：US20160251406A1

公开(公告)日：2016-09-01

申请号：US15031435

申请日：2014-10-22

申请人： THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV

发明人： Jeffrey SCHLOM ,  Kwong-Yok TSANG

IPC分类号： C07K14/47 ,  C12N7/00 ,  A61K45/06 ,  A61K39/39 ,  C07K14/82 ,  A61K39/00

CPC分类号： C07K14/4727 ,  A61K31/00 ,  A61K38/00 ,  A61K38/191 ,  A61K38/193 ,  A61K38/195 ,  A61K38/20 ,  A61K38/217 ,  A61K38/22 ,  A61K39/0011 ,  A61K39/39 ,  A61K45/06 ,  A61K2039/5154 ,  A61K2039/53 ,  A61K2039/55588 ,  C07K14/82 ,  C07K2319/00 ,  C12N7/00 ,  C12N2710/24143 ,  C12N2710/24171 ,  A61K2300/00

摘要： The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.

摘要翻译： 本发明提供了可以用作肽，多肽（蛋白质）和/或疫苗或其他组合物中的粘蛋白1（MUC1-C）的C-末端亚单位的人细胞毒性T淋巴细胞（CTL）激动剂表位 预防或治疗癌症。 本发明还提供了编码肽，蛋白质或多肽的核酸，包含核酸的载体，包含肽，多肽，核酸或载体的细胞及其组合物。

公开(公告)号：US20150238593A1

公开(公告)日：2015-08-27

申请号：US14566066

申请日：2014-12-10

申请人： BERNARD MOSS ,  LINDA WYATT ,  PATRICIA EARL ,  HARRIET L. ROBINSON

发明人： BERNARD MOSS ,  LINDA WYATT ,  PATRICIA EARL ,  HARRIET L. ROBINSON

IPC分类号： A61K39/21 ,  C12N15/86 ,  C07K14/005

CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K2039/525 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/70 ,  C07K14/005 ,  C12N15/86 ,  C12N2710/24143 ,  C12N2710/24171 ,  C12N2740/15022 ,  C12N2740/15034 ,  C12N2740/16034 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2830/00 ,  C12N2830/15 ,  C12N2830/60

摘要： The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.

摘要翻译： 本发明提供了修饰的病毒安卡拉（MVA），一种表达人免疫缺陷病毒（HIV）env，gag和pol基因的痘苗病毒复制缺陷型菌株。

公开(公告)号：US20150150967A1

公开(公告)日：2015-06-04

申请号：US14620920

申请日：2015-02-12

申请人： Centre National De La Recherche Scientifique

发明人： Yasemin ATAMAN-ONAL ,  Thierry DELAIR ,  Bernard VERRIER

IPC分类号： A61K39/39 ,  A61K47/48 ,  A61K39/21 ,  A61K39/235 ,  A61K39/285 ,  C12N7/00

CPC分类号： A61K39/39 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/21 ,  A61K39/235 ,  A61K39/285 ,  A61K47/34 ,  A61K47/482 ,  A61K47/48792 ,  A61K47/48853 ,  A61K47/48876 ,  A61K47/593 ,  A61K47/6905 ,  A61K47/6921 ,  A61K47/6927 ,  A61K2039/523 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/55583 ,  A61K2039/57 ,  A61K2039/575 ,  A61K2039/6087 ,  A61K2039/6093 ,  C12N7/00 ,  C12N2710/10041 ,  C12N2710/10071 ,  C12N2710/10343 ,  C12N2710/24141 ,  C12N2710/24143 ,  C12N2710/24171 ,  C12N2740/16034 ,  C12N2740/16071 ,  C12N2740/16234

摘要： A method of vaccination against a viral, bacterial or non-infectious disease includes administering an effective dose of a prime vaccine and then an effective dose of a boost vaccine. Each one of the prime vaccine and the boost vaccine includes an active principle. The prime vaccine includes, as the active principle, a colloidal synthetic bioresorbable vector that includes at least one protein substance. The boost vaccine includes, as the active principle, a viral vector that includes at least one nucleotide sequence which codes for a protein substance corresponding to the at least one protein substance of the synthetic vector.

摘要翻译： 针对病毒，细菌或非传染性疾病接种疫苗的方法包括施用有效剂量的初次疫苗，然后施用有效剂量的加强疫苗。 每种主要疫苗和增效疫苗都包括一种有效的原则。 主要疫苗包括作为活性成分的包含至少一种蛋白质物质的胶体合成生物可再吸收载体。 增效疫苗包括作为活性成分的病毒载体，该病毒载体包含至少一个核苷酸序列，其编码对应于合成载体的至少一种蛋白质物质的蛋白质物质。

公开(公告)号：US08901093B2

公开(公告)日：2014-12-02

申请号：US10579025

申请日：2004-11-12

申请人： Dennis L. Panicali ,  Gail P. Mazzara ,  Linda R. Gritz ,  Jeffrey Schlom ,  Kwong-Yok Tsang ,  James W. Hodge

发明人： Dennis L. Panicali ,  Gail P. Mazzara ,  Linda R. Gritz ,  Jeffrey Schlom ,  Kwong-Yok Tsang ,  James W. Hodge

IPC分类号： A61K48/00 ,  C12N5/00 ,  C12N5/02 ,  C12N15/00 ,  A61K39/00 ,  A61K39/38 ,  A61K39/225 ,  A01N63/00 ,  A01N65/00 ,  C12N15/86 ,  C12N7/00

CPC分类号： C12N15/86 ,  A61K39/0011 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/55516 ,  C12N7/00 ,  C12N2710/24043 ,  C12N2710/24071 ,  C12N2710/24143 ,  C12N2710/24171

摘要： The present invention is directed to a system for treating individuals at risk of developing or suffering from pancreatic cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains a foreign nucleic acid encoding at least one pancreatic tumor associated antigen (PTAA).

摘要翻译： 本发明涉及用于治疗患有胰腺癌发展或患有胰腺癌风险的个体的系统。 该系统包括向个体施用重组痘病毒，其中痘病毒含有编码至少一种胰腺肿瘤相关抗原（PTAA）的外源核酸。